Scientific Study
Access to over 2,900 scientific references, studies and publications. This section is constantly updated with studies that have been published in scientific journals.
Products: Dried Cranberry
Notice: Undefined variable: post in /home/nimianet/domains/test.nimia.net/public_html/wp-content/mu-plugins/custom-studies.php on line 744
Notice: Trying to get property 'ID' of non-object in /home/nimianet/domains/test.nimia.net/public_html/wp-content/mu-plugins/custom-studies.php on line 744
Cranberries and Cancer: An Update of Preclinical Studies Evaluating the Cancer Inhibitory Potential of Cranberry and Cranberry Derived Constituents.
Authors: Weh KM, Clarke J, Kresty LA.
- Journals: Antioxidants (Basel)
- Pages: 145-8
- Volume: Aug 18;5(3)
- Year: 2016
Notice: Undefined variable: post in /home/nimianet/domains/test.nimia.net/public_html/wp-content/mu-plugins/custom-articles.php on line 247
Notice: Trying to get property 'ID' of non-object in /home/nimianet/domains/test.nimia.net/public_html/wp-content/mu-plugins/custom-articles.php on line 247
Cranberries are rich in bioactive constituents reported to influence a variety of health benefits, ranging from improved immune function and decreased infections to reduced cardiovascular disease and more recently cancer inhibition. A review of cranberry research targeting cancer revealed positive effects of cranberries or cranberry derived constituents against 17 different cancers utilizing a variety of in vitro techniques, whereas in vivo studies supported the inhibitory action of cranberries toward cancers of the esophagus, stomach, colon, bladder, prostate, glioblastoma and lymphoma. Mechanisms of cranberry-linked cancer inhibition include cellular death induction via apoptosis, necrosis and autophagy; reduction of cellular proliferation; alterations in reactive oxygen species; and modification of cytokine and signal transduction pathways. Given the emerging positive preclinical effects of cranberries, future clinical directions targeting cancer or premalignancy in high risk cohorts should be considered.